Integrated Diagnostics Holdings (Integrated Diagnostics Holdings) Net Change in Cash : $-1.18 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Integrated Diagnostics Holdings Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Integrated Diagnostics Holdings's Net Change in Cash for the three months ended in Mar. 2024 was $1.40 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.18 Mil.

Integrated Diagnostics Holdings Net Change in Cash Historical Data

The historical data trend for Integrated Diagnostics Holdings's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integrated Diagnostics Holdings Net Change in Cash Chart

Integrated Diagnostics Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

-0.23

12.19

18.54

-9.86

0.83

Integrated Diagnostics Holdings Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23	Mar24
Net Change in Cash	Get a 7-Day Free Trial															4.83	-3.02	-2.58	-	1.40

Integrated Diagnostics Holdings Net Change in Cash Calculation

Integrated Diagnostics Holdings's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	17.588	+	-7.892	+	-10.691	+	1.827
	=	0.83

Integrated Diagnostics Holdings's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 2.541 + -1.22 + -2.346 + 2.426

= 1.40

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Integrated Diagnostics Holdings Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Integrated Diagnostics Holdings's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Integrated Diagnostics Holdings (Integrated Diagnostics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Integrated Diagnostics Holdings PLC (OTCPK:IDGXF) » Definitions » Net Change in Cash

Comparable Companies

LSE:DXRX LSE:AGL LSE:LLAI LSE:PRM LSE:ABDX LSE:VRCI LSE:GDR LSE:GENI TMO DHR SHSE:603259 IDXX IQV A XSWX:LONN MTD ICLR ILMN LH DGX

Traded in Other Exchanges

IDHCl:UK IDHC:UK IDHC.CA:Egypt 8I8:Germany

Address

12 Castle Street, Saint Helier, JEY, JE2 3RT

Website

https://www.idhcorp.com

Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider. It is a fully integrated diagnostics service provider operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segment- Contract Segment and Walk-in Segment. It derives majority of its revenue from services offered in Egypt.

Integrated Diagnostics Holdings (Integrated Diagnostics Holdings) Headlines

From GuruFocus

Equity Portfolio as a Savings Account
By Steven CHEN • 09-24-2021